Skip to main content
NASDAQ:MDVL

MedAvail Stock Forecast, Price & News

$11.40
+0.54 (+4.97 %)
(As of 05/14/2021 01:20 PM ET)
Add
Compare
Today's Range
$11.06
$11.40
50-Day Range
$11.50
$15.03
52-Week Range
$9.00
$46.20
Volume299 shs
Average Volume88,184 shs
Market Capitalization$364.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
30 days | 90 days | 365 days | Advanced Chart
Receive MDVL News and Ratings via Email

Sign-up to receive the latest news and ratings for MedAvail and its competitors with MarketBeat's FREE daily newsletter.


MedAvail logo

About MedAvail

MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDVL
CUSIPN/A
CIKN/A
Phone905-812-0023
Employees137
Year FoundedN/A

Sales & Book Value

Annual Sales$1.03 million
Book Value$1.54 per share

Profitability

Net Income$-4,260,000.00
Net Margins-245.38%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$364.18 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

120th out of 2,039 stocks

Pharmaceutical Preparations Industry

47th out of 769 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











MedAvail (NASDAQ:MDVL) Frequently Asked Questions

Is MedAvail a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MedAvail in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MedAvail stock.
View analyst ratings for MedAvail
or view top-rated stocks.

What stocks does MarketBeat like better than MedAvail?

Wall Street analysts have given MedAvail a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MedAvail wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MedAvail's next earnings date?

MedAvail is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for MedAvail
.

How were MedAvail's earnings last quarter?

MedAvail Holdings, Inc (NASDAQ:MDVL) released its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.01. MedAvail had a negative trailing twelve-month return on equity of 168.39% and a negative net margin of 245.38%.
View MedAvail's earnings history
.

What guidance has MedAvail issued on next quarter's earnings?

MedAvail issued an update on its FY 2021 earnings guidance on Wednesday, May, 12th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $27 million-$31 million, compared to the consensus revenue estimate of $30.03 million.

What price target have analysts set for MDVL?

2 Wall Street analysts have issued 12-month price targets for MedAvail's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate MedAvail's share price to reach $20.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price.
View analysts' price targets for MedAvail
or view top-rated stocks among Wall Street analysts.

Who are MedAvail's key executives?

MedAvail's management team includes the following people:
  • Mr. Edwin J. Kilroy, Pres, CEO & Director (Age 61, Pay $338.26k)
  • Mr. William Misloski, Chief Marketing Officer (Age 51, Pay $416k)
  • Mr. Neil Prezioso, Chief Pharmacy Officer (Age 62, Pay $408.33k)
  • Mr. Ryan Ferguson, CFO, Treasurer & Sec. (Age 46)
  • Mr. George Burrows, VP of Operations & Vendor Management
  • Mr. Fraser Mackay, Chief Information Officer (Age 51)
  • Ms. Lisa Lutich, VP of HR
  • Mr. David Rawlins, Chief Commercial Officer (Age 41)

Who are some of MedAvail's key competitors?

What is MedAvail's stock symbol?

MedAvail trades on the NASDAQ under the ticker symbol "MDVL."

Who are MedAvail's major shareholders?

MedAvail's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pura Vida Investments LLC (7.33%), Cigna Investments Inc. New (1.61%), Royce & Associates LP (0.37%), Citigroup Inc. (0.06%), Geode Capital Management LLC (0.04%) and Burleson & Company LLC (0.01%).
View institutional ownership trends for MedAvail
.

Which institutional investors are selling MedAvail stock?

MDVL stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC.
View insider buying and selling activity for MedAvail
or view top insider-selling stocks.

Which institutional investors are buying MedAvail stock?

MDVL stock was acquired by a variety of institutional investors in the last quarter, including Cigna Investments Inc. New, Royce & Associates LP, Geode Capital Management LLC, Citigroup Inc., and Burleson & Company LLC.
View insider buying and selling activity for MedAvail
or or view top insider-buying stocks.

How do I buy shares of MedAvail?

Shares of MDVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MedAvail's stock price today?

One share of MDVL stock can currently be purchased for approximately $11.40.

How much money does MedAvail make?

MedAvail has a market capitalization of $364.18 million and generates $1.03 million in revenue each year. The company earns $-4,260,000.00 in net income (profit) each year or ($5.52) on an earnings per share basis.

How many employees does MedAvail have?

MedAvail employs 137 workers across the globe.

What is MedAvail's official website?

The official website for MedAvail is www.medavail.com.

Where are MedAvail's headquarters?

MedAvail is headquartered at 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927.

How can I contact MedAvail?

MedAvail's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 905-812-0023 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.